Budesonide

證據等級: L5

預測適應症: 10 個

Budesonide: Repurposing Evaluation Incomplete — No Predictions Available

One-Sentence Summary

Budesonide (DrugBank: DB01222) is a synthetic glucocorticoid with established anti-inflammatory properties. This Evidence Pack contains no TxGNN-predicted new indications, and two critical data items — mechanism of action and TFDA package insert safety data — have not been successfully extracted. A full repurposing evaluation cannot proceed until these gaps are resolved.

Quick Overview

Item	Content
Original Indication	Not available in this Evidence Pack
Predicted New Indication	None — TxGNN predictions not loaded
TxGNN Prediction Score	N/A
Evidence Level	N/A
Taiwan Market Status	Not marketed (0 TFDA authorizations found)
Number of Authorizations	0
Recommended Decision	Hold

Why the Evaluation Cannot Proceed

Three structural issues prevent this report from being completed in standard format:

1. No predicted indications The predicted_indications field is empty. TxGNN has not returned any candidate new indications for Budesonide in this Evidence Pack. Without a repurposing hypothesis, there is no clinical trial evidence to surface, no mechanism bridge to explain, and no benefit-risk ratio to weigh.

2. Mechanism of action unavailable (DG002 — High severity) DrugBank was queried successfully and returned one record, but MOA data was not extracted into the pack. Without MOA, mechanistic plausibility cannot be assessed for any future predicted indication.

3. TFDA safety data missing (DG001 — Blocking severity) The TFDA package insert query returned a result, but warnings and contraindications were not parsed into the safety fields. This is classified as Blocking — the safety pre-screening step is formally incomplete, and no candidate can advance to clinical feasibility review under this status.

Data quality note: The query log shows both the DrugBank query (ID 3) and the TFDA package insert query (ID 4) as success with result_count: 1. The data gaps therefore reflect an extraction or parsing failure, not a source availability problem. Re-running the extraction pipeline should recover this information without needing to re-query upstream sources.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: No TxGNN repurposing predictions are present in this Evidence Pack. Even if predictions were added, two blocking/high-severity data gaps — missing safety extractions and missing MOA — would prevent the evaluation from clearing mandatory pre-screening gates.

To proceed, the following is needed:

Re-run extraction pipeline on the already-retrieved DrugBank record and TFDA package insert PDF to populate MOA and safety fields — the source documents are confirmed available
Load TxGNN prediction results for Budesonide into the Evidence Pack (predicted_indications must be populated before any evaluation work begins)
Re-verify Taiwan market status: TFDA licensing query returned 0 results, but Budesonide has internationally marketed branded products (e.g., Rhinocort®, Pulmicort®, Entocort®); a re-query using alternative trade names or ATC code R03BA02 / A07EA06 may surface existing authorizations
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.